statistiche ricercatore

Nazione	#
US - Stati Uniti d'America	390
SG - Singapore	164
VN - Vietnam	123
IT - Italia	94
CN - Cina	92
HK - Hong Kong	46
BR - Brasile	45
DE - Germania	35
FR - Francia	27
ZA - Sudafrica	25
RU - Federazione Russa	22
IE - Irlanda	16
AR - Argentina	11
IN - India	10
CA - Canada	9
IQ - Iraq	8
NL - Olanda	8
CZ - Repubblica Ceca	7
GB - Regno Unito	7
JP - Giappone	7
KR - Corea	7
MX - Messico	7
CI - Costa d'Avorio	6
FI - Finlandia	6
EC - Ecuador	5
BD - Bangladesh	4
MA - Marocco	4
SE - Svezia	4
PH - Filippine	3
PK - Pakistan	3
UA - Ucraina	3
AE - Emirati Arabi Uniti	2
AT - Austria	2
CH - Svizzera	2
CO - Colombia	2
ID - Indonesia	2
MY - Malesia	2
PE - Perù	2
TH - Thailandia	2
TR - Turchia	2
VE - Venezuela	2
BE - Belgio	1
BH - Bahrain	1
BO - Bolivia	1
CL - Cile	1
DZ - Algeria	1
EE - Estonia	1
EG - Egitto	1
ES - Italia	1
IR - Iran	1
JM - Giamaica	1
KE - Kenya	1
KG - Kirghizistan	1
KW - Kuwait	1
KZ - Kazakistan	1
LB - Libano	1
LT - Lituania	1
LV - Lettonia	1
MN - Mongolia	1
MU - Mauritius	1
MZ - Mozambico	1
NP - Nepal	1
OM - Oman	1
PL - Polonia	1
PS - Palestinian Territory	1
PY - Paraguay	1
SK - Slovacchia (Repubblica Slovacca)	1
SY - Repubblica araba siriana	1
TC - Turks e Caicos	1
TN - Tunisia	1
UZ - Uzbekistan	1
Totale	1.248

Nome	#
Identification of PSMB4 and PSMD4 as novel target genes correlated with 1q21 amplification in patients with smoldering myeloma and multiple myeloma	161
Follow-up of humoral and cellular immune responses after the third SARS-CoV-2 vaccine dose in multiple myeloma patients	151
A personalized molecular approach in multiple myeloma: the possible use of RAF/RAS/MEK/ERK and BCL-2 inhibitors	140
The impact of CD56 expression in smoldering myeloma patients on early progression	134
CD38 expression by plasma cells in extramedullary multiple myeloma	133
Oncolytic viruses: a potential breakthrough immunotherapy for multiple myeloma patients	114
Immune response to SARS-CoV-2 mRNA vaccination and booster dose in patients with multiple myeloma and monoclonal gammopathies: impact of Omicron variant on the humoral response	109
High glutamate levels in the bone marrow of multiple myeloma patients promote osteoclast formation: a novel target for osteolytic bone disease	99
Metabolic features of myeloma cells in the context of bone microenvironment: Implication for the pathophysiology and clinic of myeloma bone disease	89
Pygo2 Is Overexpressed in Myeloma Cells With 1q21 Amplification Being Involved in Carfilzomib Resistance	84
B7-H3 nanobody-based CAR T cells control multiple myeloma growth, while dual BCMA/B7-H3 CAR T cells overcome antigen escape	49
Totale	1.263

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2022/2023	34	0	0	0	0	1	2	3	1	17	5	3	2
2023/2024	86	4	3	2	6	4	16	7	3	4	5	10	22
2024/2025	288	9	6	14	29	22	16	24	22	33	25	31	57
2025/2026	855	59	71	153	73	100	72	100	46	117	64	0	0
Totale													1.263